Germany's Apceth Biopharma gets contract to manufacture EU-approved Zynteglo

apceth Biopharma
Germany CDMO Apceth Biopharma has won the contract to produce Bluebird Bio’s recently EU-approved Zynteglo. (apceth)

Germany’s Apceth Biopharma, a CDMO focused on cell and gene therapeutics, has won the contract to produce Bluebird Bio’s recently EU-approved Zynteglo.

The European Commission granted conditional marketing authorization Monday for Zynteglo, which is a gene therapy designed to treat transfusion-dependent β-thalassemia (TDT).

Zynteglo adds functional copies of an altered form of the β-globin gene into TDT patients’ own blood stem cells. The inserted genes then produce hemoglobin at normal levels, reducing or eliminating the need for the frequent blood transfusions that TDT patients generally receive.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“We are proud to be the commercial manufacturing partner of Bluebird Bio and to be part of bringing this life-changing therapy to TDT patients in Europe,” Christine Guenther, M.D., Apceth’s chief excecutive, said in a statement. “Being one of the very few companies worldwide to manufacture a cell-based gene therapy for commercial use marks a milestone for our company.”

Bluebird has said it expects to file for FDA approval of Zynteglo by the end of the year.

In April, Hitachi Chemical completed its $86.8 million acquisition of Apceth in a deal that gave the Japanese conglomerate two manufacturing sites in Munich with 6,458 square feet of cleanroom space.

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.